The problem of non-compliance in schizophrenia: Opinions of patients and their relatives. A pilot study

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue 2, 2000, Pages 147-150

  Parashos, Ioannis A ^a   Xiromeritis, Konstantinos ^b   Zoumbou, Vassiliki ^b   Stamouli, Sophia ^c   Theodotou, Rita ^a  

^a H LUNDBECK A S   (Denmark)

^b Multilingual Counselling Service   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Compliance; Patients' education; Patients' opinions; Relapses; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DOCTOR PATIENT RELATION; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 0033931968     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651500009178001     Document Type: Article

References (20)

1. Carpenter WT, Jr (1996) Maintenance therapy of persons with schizophrenia. J Clin Psychiatry 57 (suppl. 9): 10-18.
2. Kissling W (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 89 (suppl. 382): 16-24.
3. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr (1993) Principles and practice of psychopharmacotherapy, 118-33. Williams & Wilkins, Baltimore, MD.
4. Weiden P, Aquila R, Standard J (1996) Atypical antipsychotic drugs and the long-term outcome in schizophrenia. J Clin Psychiatry 57 (suppl. 11): 53-60.
5. Gaebel W (1997) Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 12 (suppl. 1): S37-S42.
6. Kissling W (ed) (1991) Guidelines for neuroleptic relapse prevention in schizophrenia. Springer-Verlag, Berlin.
7. Bebbington PE (1995) The content and context of compliance. Int Clin Psychopharmacol 9 (suppl. 5): 41-50.
8. Awad AG, Hogan TP, Voruganti LNP, Heslegrave RJ (1995) Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 10 (suppl. 3): 123-32.
9. Awad AG, Voruganti LNP, Heslegrave RJ, Hogan TP (1996) Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 11 (suppl. 2): 55-9.
10. Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 23(4): 637-51.
11. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (3rd edn rev.) (DSM-IIIR). APA Press, Washington, DC.
12. Mosteller F, Fienberg SE, Rourke REK (1983) Beginning statistics with data analysis. Addison-Wesley, Reading, MA.
13. Fleischhaker WW, Meise U, Gunther V, Kurz M (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 89 (suppl. 382): 11-15.
14. Kane JM (1997) What can we achieve by implementing a compliance improvement program? Int Clin Psychopharmacol 12 (suppl. 1): S43-S46.
15. Bauml J, Kissling W, Buttner P et al (1993) Central information and classification for improving compliance in patients with schizophrenic psychoses (in German). Verhaltenstherapie 3 (suppl. 1): 1-96.
16. Chan DW (1994) Medication compliance in a Chinese psychiatric outpatient setting. Br J Med Psychol 57: 81-9.
17. Penn DL, Mueser KT (1996) Research update on the psychosocial treatments of schizophrenia. Am J Psychiatry 153: 607-17.
18. Nelson AA, Gold BH, Hachinson RA, Benezra E (1975) Drug default among schizophrenic patients. Am J Hosp Pharmacy 32: 1237-42.
19. Marder SR, Mebane A, Chien C-P et al (1983) A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 140: 470-2.
20. Hogan TP, Awad AG, Eastwood MR (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 13: 177-83.